As expected, Abbott posted strong fourth quarter and full year results for Libre. Let’s take a quick look at the numbers in the fourth quarter global sales reached $691 million, full year global just over $2.5 Billion. No matter how you slice these numbers they are impressive, but the scary part is they are just the tip of the iceberg. As we keep noting CGM adoption will only increase in the future as it becomes the standard for glucose measurement regardless of the patient’s therapy regimen. Simply put CGM isn’t just for intensive insulin users anymore . . .
This content is restricted to subscribers. Please subscribe.
Already have an account? Please login.